Universe Pharmaceuticals INC
UPC
$2.91
-$0.71-19.61%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -14.14% | -14.14% | -26.74% | -30.23% | -30.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.14% | -14.14% | -26.74% | -30.23% | -30.23% |
| Cost of Revenue | -25.12% | -25.12% | -22.96% | -22.89% | -22.89% |
| Gross Profit | 16.06% | 16.06% | -35.45% | -45.02% | -45.02% |
| SG&A Expenses | -47.80% | -47.80% | 6.56% | 37.48% | 37.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -96.64% | -123.36% | -123.36% |
| Total Operating Expenses | -43.39% | -43.39% | -8.56% | -20.16% | -20.16% |
| Operating Income | 90.62% | 90.62% | -52.59% | -1,266.35% | -1,266.35% |
| Income Before Tax | 93.94% | 93.94% | -39.45% | -4,901.70% | -4,901.70% |
| Income Tax Expenses | -- | -- | -104.57% | -31.73% | -31.73% |
| Earnings from Continuing Operations | 93.89% | 93.89% | -8.04% | -1,731.34% | -1,731.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.89% | 93.89% | -8.04% | -1,731.34% | -1,731.34% |
| EBIT | 90.62% | 90.62% | -52.59% | -1,266.35% | -1,266.35% |
| EBITDA | 94.35% | 94.35% | -56.37% | -466.39% | -466.39% |
| EPS Basic | 99.76% | 99.76% | -- | -- | -- |
| Normalized Basic EPS | 99.77% | 99.77% | -- | -- | -- |
| EPS Diluted | 99.76% | 99.76% | -- | -- | -- |
| Normalized Diluted EPS | 99.77% | 99.77% | -- | -- | -- |
| Average Basic Shares Outstanding | 2,486.70% | 2,486.70% | -- | -- | -- |
| Average Diluted Shares Outstanding | 2,486.70% | 2,486.70% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |